|
1
|
Anderson KC and Carrasco RD: Pathogenesis
of myeloma. Annu Rev Pathol. 6:249–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pruneri G, Cinieri S, Peccatori F and
Viale G: Unusual cases in multiple myeloma and a dramatic response
in metastatic lung cancer: Case 2. Plasma cell myeloma coexisting
with metastatic breast carcinoma in the bone marrow. J Clin Oncol.
23:232–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naymagon L and Abdul-Hay M: Novel agents
in the treatment of multiple myeloma: A review about the future. J
Hematol Oncol. 9:522016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar SK, Lee JH, Lahuerta JJ, Morgan G,
Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau
P, et al: Risk of progression and survival in multiple myeloma
relapsing after therapy with IMiDs and bortezomib: A multicenter
international myeloma working group study. Leukemia. 26:149–157.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang S, Hu C, Liu P and Lu M:
Tumor-derived exosomes in cancer metastasis risk diagnosis and
metastasis therapy. Clin Transl Oncol. 21:152–159. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan HL, Wang T and Zhang KH: MicroRNAs as
potential biomarkers for diagnosis, therapy and prognosis of
gastric cancer. Onco Targets Ther. 11:3891–3900. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma N and Baruah MM: The microRNA
signatures: Aberrantly expressed miRNAs in prostate cancer. Clin
Transl Oncol. 21:126–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X
and Cong H: The potential function of microRNAs as biomarkers and
therapeutic targets in multiple myeloma. Oncol Lett. 15:6094–6106.
2018.PubMed/NCBI
|
|
11
|
Nobili L, Ronchetti D, Agnelli L, Taiana
E, Vinci C and Neri A: Long Non-Coding RNAs in multiple myeloma.
Genes (Basel). 9(pii): E692018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rastgoo N, Abdi J, Hou J and Chang H: Role
of epigenetics-microRNA axis in drug resistance of multiple
myeloma. J Hematol Oncol. 10:1212017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang YZ, Zhang XY, Wan Q and Li J: Role of
Exosomal miRNA in multiple myeloma progression and its possible
mechanism-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 25:301–305.
2017.(In Chinese). PubMed/NCBI
|
|
14
|
Rossi M, Tagliaferri P and Tassone P:
MicroRNAs in multiple myeloma and related bone disease. Ann Transl
Med. 3:3342015.PubMed/NCBI
|
|
15
|
Bi C and Chng WJ: MicroRNA: Important
player in the pathobiology of multiple myeloma. Biomed Res Int.
2014:5215862014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao Y, Shi X, Liu Y, Xu R and Ai Q:
MicroRNA-338-3p inhibits proliferation and promotes apoptosis of
multiple myeloma cells through targeting Cyclin-dependent kinase 4.
Oncol Res. 27:117–124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang B, Xu A, Xu J, Huang H, Chen L, Su Y,
Zhang L, Li J, Fan F, Deng J, et al: MicroRNA-324-5p regulates
stemness, pathogenesis and sensitivity to bortezomib in multiple
myeloma cells by targeting hedgehog signaling. Int J Cancer.
142:109–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alzrigat M and Jernberg-Wiklund H: The
miR-125a and miR-320c are potential tumor suppressor microRNAs
epigenetically silenced by the polycomb repressive complex 2 in
multiple myeloma. RNA Dis. 4(pii): e15292017.PubMed/NCBI
|
|
19
|
Zhang X, Chen Y, Zhao P, Zang L, Zhang Z
and Wang X: MicroRNA-19a functions as an oncogene by regulating
PTEN/AKT/pAKT pathway in myeloma. Leuk Lymphoma. 58:932–940. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hua J, Ding T and Yang L: Dysfunction of
microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma
disease. Onco Targets Ther. 9:6573–6579. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda S, Kitadate A, Abe F, Saitoh H,
Michishita Y, Hatano Y, Kawabata Y, Kitabayashi A, Teshima K, Kume
M, et al: Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4
oncogenic axis in multiple myeloma. Cancer Sci. 108:641–652. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Zhang G, Yu W, Gao N and Peng J:
miR-186 inhibits cell proliferation in multiple myeloma by
repressing Jagged1. Biochem Biophys Res Commun. 469:692–697. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saha MN, Abdi J, Yang Y and Chang H:
MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced
anti-myeloma activity by targeting c-Myc. Oncotarget. 7:7149–7160.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang B, Xu G, Lv HQ, Huang M and Li Z:
Up-regulation of miR-765 predicts a poor prognosis in patients with
esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci.
22:3789–3794. 2018.PubMed/NCBI
|
|
25
|
Liang W, Wei X, Li Q, Dai N, Li CY, Deng
Y, Jiang X, Tan XR, Dai XY, Li MX, et al: MicroRNA-765 enhances the
anti-angiogenic effect of CDDP via APE1 in Osteosarcoma. J Cancer.
8:1542–1551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie BH, He X, Hua RX, Zhang B, Tan GS,
Xiong SQ, Liu LS, Chen W, Yang JY, Wang XN and Li HP: Mir-765
promotes cell proliferation by downregulating INPP4B expression in
human hepatocellular carcinoma. Cancer Biomark. 16:405–413. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Li J, Li K and Xu J: SOX6 is
downregulated in osteosarcoma and suppresses the migration,
invasion and epithelial-mesenchymal transition via TWIST1
regulation. Mol Med Rep. 17:6803–6811. 2018.PubMed/NCBI
|
|
29
|
Li Y, Xiao M and Guo F: The role of Sox6
and Netrin-1 in ovarian cancer cell growth, invasiveness, and
angiogenesis. Tumour Biol. 39:10104283177055082017.PubMed/NCBI
|
|
30
|
Zhu Y, Xia Y, Niu H and Chen Y: MiR-16
induced the suppression of cell apoptosis while promote
proliferation in esophageal squamous cell carcinoma. Cell Physiol
Biochem. 33:1340–1348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Y, Li F, Saha MN, Abdi J, Qiu L and
Chang H: miR-137 and miR-197 induce apoptosis and suppress
tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer
Res. 21:2399–2411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J, Li J
and Chen L: Circulating microRNA 483-5p as a novel biomarker for
diagnosis survival prediction in multiple myeloma. Med Oncol.
31:2192014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma J, Liu S and Wang Y: MicroRNA-21 and
multiple myeloma: Small molecule and big function. Med Oncol.
31:942014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu Y, Wang H, Chen E, Xu Z, Chen B and Lu
G: Candidate microRNAs as biomarkers of thyroid carcinoma: A
systematic review, meta-analysis, and experimental validation.
Cancer Med. 5:2602–2614. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ding J, Yang C and Yang S: LINC00511
interacts with miR-765 and modulates tongue squamous cell carcinoma
progression by targeting LAMC2. J Oral Pathol Med. 47:468–476.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohta S, Misawa A, Lefebvre V, Okano H,
Kawakami Y and Toda M: Sox6 up-regulation by macrophage migration
inhibitory factor promotes survival and maintenance of mouse neural
stem/progenitor cells. PLoS One. 8:e743152013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang W, Yuan Q, Jiang Y, Huang L, Chen C,
Hu G, Wan R, Wang X and Yang L: Identification of Sox6 as a
regulator of pancreatic cancer development. J Cell Mol Med.
22:1864–1872. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu Y, Wang Z, Sun D, Zhou X, Wei X, Hou W,
Ding Y, Ma Y and Hou Y: miR-671 promotes prostate cancer cell
proliferation by targeting tumor suppressor SOX6. Eur J Pharmacol.
823:65–71. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li YC, Li CF, Chen LB, Li DD, Yang L, Jin
JP and Zhang B: MicroRNA-766 targeting regulation of SOX6
expression promoted cell proliferation of human colorectal cancer.
Onco Targets Ther. 8:2981–2988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo X, Yang M, Gu H, Zhao J and Zou L:
Decreased expression of SOX6 confers a poor prognosis in
hepatocellular carcinoma. Cancer Epidemiol. 37:732–736. 2013.
View Article : Google Scholar : PubMed/NCBI
|
